Clarity AD

Lecanemab: drawbacks to consider

Lecanemab: a review

FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?

Lecanemab and what this means for the future treatment of Alzheimer’s disease

The development of lecanemab & rationale behind its unique binding profile

The potential of lecanemab for the treatment of early Alzheimer’s disease

Lecanemab for the treatment of early Alzheimer’s disease: the story so far

Lecanemab: Phase II open-label extension results

Major ongoing clinical trials in AD: aducanumab, donanemab & lecanemab

Phase III AHEAD 3-45 trial of lecanemab for preclinical Alzheimer’s disease